FindTrial
Sign In

Network meta-analysis of adjuvant chemotherapy for NSCLC

Network meta-analysis of adjuvant chemotherapy for NSCLC - Adjuvant Chemotherapy for NSCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042811
Enrollment
Unknown
Registered
2020-12-22
Start date
2020-12-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early-stage non-small cell lung cancer

Interventions

None listed

Sponsors

Self sponsored
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient should have early stage (stage I-IIIa) NSCLC. Sub-pathological type of NSCLC is not questioned. Patients in at least one arm need to be treated with Cis-Vnr or Cis-Pemt. Dose and number of planned cycles of the chemotherapy are not questioned.

Exclusion criteria

Exclusion criteria: Neoadjuvant chemotherapy or pre-operative chemotherapy is not our concern.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is recurrence-free survival assessed by hazard ratio.—

Countries

Japan

Contacts

Public ContactNobuyuki Horita

Yokohama City University Department of Pulmonology

horitano@yokohama-cu.ac.jp+81457872800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026